TORONTO, Dec. 28, 2017 (GLOBE NEWSWIRE) -- Scythian Biosciences Corp. (TSX-V:SCYB) (Frankfurt:9SB) (OTC
Pink:SCCYF) (“Scythian” or the “Company”) is issuing this press release in response to a request
by the Investment Industry Regulatory Organization of Canada to comment on recent trading activity of its common shares. The
Company announces that it is not aware of any material undisclosed developments and has no material information or change to report
at this time. Scythian is also unaware of any material undisclosed change related to the Company that would explain the recent
movements in the price of its common shares. The Company will keep the market informed as required.
Scythian is a research and development company committed to finding a solution for the prevention and treatment
of concussions and traumatic brain injury with its proprietary Cannabinoid combination.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of
the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release may contain assumptions, estimates, and other forward-looking statements regarding future
events. Such forward-looking statements involve inherent risks and uncertainties and are subject to factors, many of which are
beyond the Company's control that may cause actual results or performance to differ materially from those currently anticipated in
such statements.
FOR FURTHER INFORMATION PLEASE CONTACT:
Scythian Biosciences Corp.
Jonathan Gilbert, CEO
Phone: (212) 729-9208
Email: info@scythianbio.com
